Skip to main
DNTH

DNTH Stock Forecast & Price Target

DNTH Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dianthus Therapeutics Inc. is positioned favorably due to its innovative focus on next-generation monoclonal antibodies for severe autoimmune and inflammatory diseases, which is supported by a competent executive team and an advancing clinical pipeline. The recent increase in price targets reflects improved net cash positions and a reduction in share count, enhancing the company's financial stability and growth prospects. Additionally, the licensing agreement with Nanjing Leads Biolabs for DNTH212 expands its development capabilities, underscoring the potential for broadening its therapeutic offerings and solidifying its market position.

Bears say

Dianthus Therapeutics Inc. is facing significant financial challenges, as its ability to advance its pipeline may be compromised if the company fails to secure sufficient funding. The removal of an assumed offering in fiscal year 2028 and the reduction of the fiscal year 2025 share count indicate a need for more cautious financial planning moving forward. These factors contribute to a negative outlook regarding the company's future operational capabilities and overall financial stability.

DNTH has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Magenta Therapeutics Inc (DNTH) Forecast

Analysts have given DNTH a Strong Buy based on their latest research and market trends.

According to 8 analysts, DNTH has a Strong Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Magenta Therapeutics Inc (DNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.